AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Not Yet Opened 05-20 16:00:00 EDT

3.74

+0.10

+2.75%

盘后3.77

+0.03+0.80%

19:52 EDT

High3.76	Low3.58	Vol1.03M
Open3.65	D1 Closing3.64	Amplitude4.95%
Mkt Cap1.10B	Tradable Cap704.18M	Total Shares293.92M
T/O3.84M	T/O Rate0.55%	Tradable Shares188.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":3.74,"timestamp":1716235200000,"preClose":3.64,"halted":0,"volume":1034253,"hourTrading":{"tag":"盘后","latestPrice":3.77,"preClose":3.74,"latestTime":"19:52 EDT","volume":2779,"amount":10432.39,"timestamp":1716249134076},"delay":0,"floatShares":188283492,"shares":293921356,"eps":-0.510213,"marketStatus":"Not Yet Opened","change":0.1,"latestTime":"05-20 16:00:00 EDT","open":3.65,"high":3.76,"low":3.58,"amount":3837249.7988715,"amplitude":0.049451,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.510213,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716278400000},"marketStatusCode":0,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":3.64,"preHourTrading":{"tag":"盘前","latestPrice":3.69,"preClose":3.64,"latestTime":"09:26 EDT","volume":7601,"amount":27893.3076092,"timestamp":1716211605063},"postHourTrading":{"tag":"盘后","latestPrice":3.77,"preClose":3.74,"latestTime":"19:52 EDT","volume":2779,"amount":10432.39,"timestamp":1716249134076},"volumeRatio":0.8618935418485227},"requestUrl":"/m/hq/s/ABCL/tweets","defaultTab":"tweets","newsList":[{"id":"2436939151","title":"Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula","url":"https://stock-news.laohu8.com/highlight/detail?id=2436939151","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436939151?lang=en_us&edition=fundamental","pubTime":"2024-05-17 06:36","pubTimestamp":1715898967,"startTime":"0","endTime":"0","summary":"Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021.Nearly all AI-driven drug discovery companies have struggled with overall share pric","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/83803495/image_83803495.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/83803495/image_83803495.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693987-absci-ai-tag-keeping-company-afloat-while-searching-for-right-formula","is_publish_highlight":false,"gpt_icon":0},{"id":"2435672114","title":"AbCellera: If You Build It, Will They Come? Fresh Impetus Required","url":"https://stock-news.laohu8.com/highlight/detail?id=2435672114","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435672114?lang=en_us&edition=fundamental","pubTime":"2024-05-16 20:39","pubTimestamp":1715863140,"startTime":"0","endTime":"0","summary":"AbCellera's valuation has shrunk by 80% since its IPO due to the withdrawal of its COVID antiviral, bamlanivimab.The company reported Q1 2024 revenues of $10 million, down from $12.2 million in the pr","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1501249755/image_1501249755.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1501249755/image_1501249755.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693825-abcellera-if-you-build-it-will-they-come-fresh-impetus-required-abcl-stock","is_publish_highlight":false,"gpt_icon":0},{"id":"2435644888","title":"KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435644888","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435644888?lang=en_us&edition=fundamental","pubTime":"2024-05-16 14:25","pubTimestamp":1715840729,"startTime":"0","endTime":"0","summary":"In a report released today, Scott Schoenhaus from KeyBanc reiterated a Buy rating on AbCellera Biologics (ABCL – Research Report), with a price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/keybanc-reaffirms-their-buy-rating-on-abcellera-biologics-abcl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/keybanc-reaffirms-their-buy-rating-on-abcellera-biologics-abcl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435105266","title":"AbCellera: Cash Providing Shelter From Market Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2435105266","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435105266?lang=en_us&edition=fundamental","pubTime":"2024-05-16 11:17","pubTimestamp":1715829477,"startTime":"0","endTime":"0","summary":"AbCellera Biologics is a drug discovery company focused on developing antibody therapies.While the company has developed a technology platform that is open to customers, the current market environment","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441786721/image_1441786721.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441786721/image_1441786721.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693712-abcellera-cash-providing-shelter-from-market-weakness","is_publish_highlight":false,"gpt_icon":0},{"id":"2434990832","title":"Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2434990832","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434990832?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:16","pubTimestamp":1715336200,"startTime":"0","endTime":"0","summary":"These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the AbCellera Biologics' past performance and to peers in the same industry. One thing stands out from these estimates, which is that AbCellera Biologics is forecast to grow faster in the future than it has in the past, with revenues expected to display 16% annualised growth until the end of 2024. If achieved, this would be a much better result than the 49% annual decline over the past three years. Compare this against analyst estimates for the broader industry, which suggest that  industry revenues are expected to grow 6.5% annually. So","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-release-heres-why-analysts-101640868.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433742819","title":"Buy Rating Affirmed for AbCellera Biologics on Strong Financials and Promising Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2433742819","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433742819?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:18","pubTimestamp":1715167086,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on AbCellera Biologics (ABCL – Research Report), with a pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-abcellera-biologics-on-strong-financials-and-promising-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-abcellera-biologics-on-strong-financials-and-promising-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433149957","title":"AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2433149957","media":"Motley Fool Transcribing","top":-1,"share":"https://ttm.financial/m/news/2433149957?lang=en_us&edition=fundamental","pubTime":"2024-05-08 16:30","pubTimestamp":1715157012,"startTime":"0","endTime":"0","summary":"ABCL earnings call for the period ending March 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2024/05/08/abcellera-biologics-abcl-q1-2024-earnings-call-tra/","is_publish_highlight":false,"gpt_icon":0},{"id":"2433715583","title":"Analysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433715583","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433715583?lang=en_us&edition=fundamental","pubTime":"2024-05-08 15:10","pubTimestamp":1715152248,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ICU Medical (ICUI – Research Report) and AbCellera B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-icu-medical-icui-abcellera-biologics-abcl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-icu-medical-icui-abcellera-biologics-abcl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433576457","title":"AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2433576457","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2433576457?lang=en_us&edition=fundamental","pubTime":"2024-05-08 06:05","pubTimestamp":1715119507,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc.  came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.17, delivering a surprise of -21.43%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.AbCellera Biologics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.95 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 11.64%. This compares to year-ago revenues of $12.19 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a mater","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-reports-220507470.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2433075968","title":"AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2433075968","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2433075968?lang=en_us&edition=fundamental","pubTime":"2024-05-08 06:01","pubTimestamp":1715119298,"startTime":"0","endTime":"0","summary":"Revenue: Reported at $10.0 million, down from $12.2 million in Q1 2023, falling short of the estimated $10.84 million.Net Loss: Recorded a net loss of $40.6 million, slightly below above the estimated net loss of $48.13 million.Earnings Per Share : Reported at -$0.14, exceeding the estimated EPS of -$0.17.Liquidity: Ended the quarter with $725.3 million in cash, cash equivalents, and marketable securities, showcasing a strong financial position.Partner-initiated Programs: Increased to 90 starts, up from 75 last year, indicating a 20% growth and potential for future revenue through partnerships.On May 7, 2024, AbCellera Biologics Inc  released its financial results for the first quarter of 2024 through an 8-K filing. The company, known for its advanced antibody discovery and development platform, reported a challenging quarter with revenues and net loss figures that did not meet analyst expectations.AbCellera's R&D expenses saw a significant reduction to $39.3 million from $52.6 million","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ziKsj4Y7iTe7ZW3b5tCJlg--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/f488b98e51b36bb867a10820aac600e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ziKsj4Y7iTe7ZW3b5tCJlg--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/f488b98e51b36bb867a10820aac600e6"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-q1-220138751.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433153737","title":"AbCellera Biologics Reviews Q1 Earnings with Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2433153737","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433153737?lang=en_us&edition=fundamental","pubTime":"2024-05-08 04:33","pubTimestamp":1715114018,"startTime":"0","endTime":"0","summary":"An update from AbCellera Biologics (ABCL) is now available. On May 7, 2024, during its earnings call, the Company will review its first-quarter res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-reviews-q1-earnings-with-corporate-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-reviews-q1-earnings-with-corporate-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433509732","title":"AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2433509732","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2433509732?lang=en_us&edition=fundamental","pubTime":"2024-05-08 04:13","pubTimestamp":1715112820,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent.  The company reported quarterly sales of $9.954 million which missed","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38681951/abcellera-biologics-q1-2024-gaap-eps-0-14-beats-0-16-estimate-sales-9-954m-miss-10-836m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2433737909","title":"AbCellera Reports Q1 2024 Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2433737909","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433737909?lang=en_us&edition=fundamental","pubTime":"2024-05-08 04:05","pubTimestamp":1715112300,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, May 07, 2024----AbCellera  today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.\"We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships,\" said Carl Hansen, Ph.D., founder and CEO of AbCellera. \"This quarter, presentations on our T-cell engager platform, which includes our highly differentiated CD3 panel, demonstrated how we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release. With our TCE platform in place, we are moving programs towards in vivo studies.\". Presented new data on its T-cell engager  programs at the American Association for Cancer Research Annual Meeting 2024 that demonstrate how AbCellera's TCE platform is able to generate TCEs that achieve potent cell killing with low toxicity ass","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3ShoZUm4tJyMDjRSyX0B9w--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0beeebd16ecdf086d7e0daab5bd2a238","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3ShoZUm4tJyMDjRSyX0B9w--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0beeebd16ecdf086d7e0daab5bd2a238"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-reports-q1-2024-business-200500992.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433227713","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2433227713","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433227713?lang=en_us&edition=fundamental","pubTime":"2024-05-07 18:00","pubTimestamp":1715076000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Alph and Omg Smcn                                 3Q      (.14)   4:01 PM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432598108","title":"Insider Stock Buying Reaches US$1.61m On AbCellera Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2432598108","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432598108?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:15","pubTimestamp":1714662908,"startTime":"0","endTime":"0","summary":"Quite a few insiders have dramatically grown their holdings in AbCellera Biologics Inc.  over the past 12 months. An insider's optimism about the company's prospects is a positive sign.Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.AbCellera Biologics Insider Transactions Over The Last Year. The CEO, President & Chairperson Carl Hansen made the biggest insider purchase in the last 12 months. That single transaction was for US$998k worth of shares at a price of US$6.52 each. That means that even when the share price was higher than US$3.78 , an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-stock-buying-reaches-us-151508642.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432269691","title":"Tracking Baillie Gifford's 13F Portfolio - Q1 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2432269691","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432269691?lang=en_us&edition=fundamental","pubTime":"2024-05-02 10:07","pubTimestamp":1714615623,"startTime":"0","endTime":"0","summary":"Baillie Gifford's 13F portfolio value increased from ~$126B to ~$129B this quarter.The top three holdings in the portfolio are NVIDIA, MercadoLibre, and Amazon.com.Baillie Gifford made stake increases","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318776826/image_1318776826.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318776826/image_1318776826.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688300-tracking-baillie-giffords-13f-portfolio-q1-2024-update","is_publish_highlight":false,"gpt_icon":1},{"id":"2432504675","title":"Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2432504675","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432504675?lang=en_us&edition=fundamental","pubTime":"2024-05-01 22:01","pubTimestamp":1714572088,"startTime":"0","endTime":"0","summary":"Cytokinetics  is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 8, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.This biopharmaceutical company is expected to post quarterly loss of $1.16 per share in its upcoming report, which represents a year-over-year change of +15.9%.Revenues are expected ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytokinetics-cytk-may-report-negative-140128917.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432574693","title":"BRIEF-Abcellera, Viking Global Investors And Arrowmark Partners Collaborate To Launch New Biotech Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2432574693","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432574693?lang=en_us&edition=fundamental","pubTime":"2024-05-01 21:15","pubTimestamp":1714569331,"startTime":"0","endTime":"0","summary":"May 1  - Abcellera Biologics Inc   :   * ABCELLERA, VIKING GLOBAL INVESTORS, AND ARROWMARK PARTNERS COLLABORATE TO LAUNCH NEW BIOTECH COMPANIES   * ABCELLERA BIOLOGICS INC: UNDER TERMS OF COLLABORATION, VIKING AND ARROWMARK WILL BE MAJORITY SHAREHOLDERS OF NEWCOS   * ABCELLERA:UNDER TERMS, ABCELLERA WILL PARTICIPATE AS EQUITY FOUNDING PARTNER WITH POTENTIAL FOR MILESTONES, ROYALTIES ON FUTURE SALES OF EACH PRODUCTSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432503646","title":"AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2432503646","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432503646?lang=en_us&edition=fundamental","pubTime":"2024-05-01 21:00","pubTimestamp":1714568400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, May 01, 2024----AbCellera , Viking Global Investors , and ArrowMark Partners  announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology.The collaboration brings together Viking and ArrowMark’s expertise in early-stage investing and company creation with AbCellera’s engine for discovering and developing antibody medicines. Under the collaboration, ArrowMark and Viking will lead the initial process of program selection, followed by joint determination of the therapeutic product profile and AbCellera’s initiation of new antibody drug programs. AbCellera will advance programs to development candidates and has an option to conduct cGMP manufacturing to support Phase 1 clinical trials. Successful programs will be further developed through the creation of Newcos, with Viking and ArrowMark funding work through to com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SFKdCL4cHo4eRPlkjQQIyw--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/784a0b5aff63c1d80eaaf783613d529c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SFKdCL4cHo4eRPlkjQQIyw--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/784a0b5aff63c1d80eaaf783613d529c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-viking-global-investors-arrowmark-130000113.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":-0.0286},{"period":"1month","weight":-0.0336},{"period":"3month","weight":-0.2957},{"period":"6month","weight":-0.1558},{"period":"1year","weight":-0.3596},{"period":"ytd","weight":-0.345}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0705},{"period":"3month","weight":0.067},{"period":"6month","weight":0.1649},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.1152}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.031012},{"month":2,"riseRate":0,"avgChangeRate":-0.132842},{"month":3,"riseRate":0.25,"avgChangeRate":-0.046348},{"month":4,"riseRate":0,"avgChangeRate":-0.173736},{"month":5,"riseRate":0.5,"avgChangeRate":0.004419},{"month":6,"riseRate":0.333333,"avgChangeRate":0.048148},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.057046},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.041693},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011885},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.042144},{"month":11,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.014901}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction